The cost-effectiveness of bevacizumab for the treatment of advanced ovarian cancer in Canada | Duong | Current Oncology Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Wednesday, October 26, 2016

The cost-effectiveness of bevacizumab for the treatment of advanced ovarian cancer in Canada | Duong | Current Oncology



open access

CONCLUSIONS

The present analysis provides supportive evidence to inform the potential cost-effectiveness, in the frontline setting, of the addition of bevacizumab to standard chemotherapy in ovarian cancer patients at a high risk of progression.

0 comments :

Post a Comment

Your comments?